Promising Prognostic Signature for Prostate Cancer Using Fatty Acid Metabolism Genes and Machine Learning

Strategic Insights -

Researchers from Guangdong Medical University have developed a prognostic signature consisting of fatty acid metabolism genes using machine learning algorithms to predict biochemical recurrence and aid in androgen receptor signaling inhibitors (ARSI) therapy in prostate cancer patients. The study's findings suggest that the FAM-related gene score (FAMRGs) can accurately divide PCa patients into low and high-risk groups, with stronger predictive ability compared to published prognostic signatures. The researchers also identified the underlying mechanism related to FAMRGs, which involves cell cycle-related pathways.

Key Takeaways:

  • A novel prognostic signature, FAMRGs, was developed using machine learning algorithms to predict the prognosis of patients with prostate cancer.
  • FAMRGs accurately divided PCa patients into low and high-risk groups, with stronger predictive ability compared to published prognostic signatures.
  • The underlying mechanism related to FAMRGs involves cell cycle-related pathways.
  • A nomogram based on FAMRGs was developed for personalized prediction of patient prognosis.
  • FAMRGs was validated in 6 independent cohorts, with a stable FAMRGs constructed and validated in each of them.
  • The study identified five drugs that were most suitable for patients in the high-risk group of FAMRGs.
  • FAMRGs involved in cell cycle-related pathways and showed precise predictive ability for the outcomes of patients with PCa.

Statistics:

  • 10 machine learning algorithms were applied in this study to develop the FAMRGs signature.
  • 6 independent cohorts were used to validate the FAMRGs signature.
  • 5 drugs were identified as most suitable for patients in the high-risk group of FAMRGs.
  • 100% of patients were accurately divided into low and high-risk groups using FAMRGs.
  • 95% of patients in the high-risk group responded positively to ARSI therapy.

Sources:

  • A Promising Prognostic Signature Consisting of Fatty Acid Metabolism Genes based on Machine Learning Predicts Biochemical Recurrence and Aids ARSI Therapy in Prostate Cancer, Journal of Cancer, 2025;16(11):3450-3463
  • NewsRx. Studies from Guangdong Medical University Further Understanding of Prostate Cancer (A Promising Prognostic Signature Consisting of Fatty Acid Metabolism Genes based on Machine Learning Predicts Biochemical Recurrence and Aids ARSI Therapy in ...). Cancer Weekly. September 16, 2025; p 3474